StocksMedium•27 October 2026•
1 min read
Aclaris Therapeutics Prices $50 Million Public Offering of Common Stock
Key Facts
1Aclaris Therapeutics announced the pricing of a public offering of common stock and pre-funded warrants to raise $50 million.
2The offering price was set at $3.50 per share, including over 7.7 million shares of common stock.
Aclaris Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants to raise gross proceeds of approximately $50 million. GlobeNewswire reported that the offering price was set at $3.50 per share, consisting of 7,785,714 shares of common stock and 6,500,000 pre-funded warrants.
The company intends to use the proceeds to fund its clinical-stage biopharmaceutical development focused on immuno-inflammatory diseases. ACRS closed at $3.79 on October 26, 2026, reflecting a premium over the announced public offering price.